Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ: PIRS · Real-Time Price · USD
16.01
+0.54 (3.49%)
Nov 20, 2024, 4:00 PM EST - Market closed
Pieris Pharmaceuticals Employees
As of December 31, 2023, Pieris Pharmaceuticals had 50 total employees, including 46 full-time and 4 part-time employees. The number of employees decreased by 94 or -65.28% compared to the previous year.
Employees
50
Change (1Y)
-94
Growth (1Y)
-65.28%
Revenue / Employee
$27,040
Profits / Employee
-$319,060
Market Cap
21.20M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bolt Biotherapeutics | 100 |
VSee Health | 40 |
Movano | 30 |
Spruce Biosciences | 29 |
BriaCell Therapeutics | 16 |
iBio, Inc. | 16 |
NeuroOne Medical Technologies | 16 |
Cocrystal Pharma | 12 |
PIRS News
- 5 weeks ago - Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewsWire
- 3 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - GlobeNewsWire
- 4 months ago - PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS - Business Wire
- 4 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc. - PRNewsWire
- 4 months ago - Dr. Vince Clinical Research Presents Groundbreaking Webinar on Accelerating Clinical & Drug Development Timelines with AI - Business Wire
- 4 months ago - Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Accesswire
- 7 months ago - Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split - Accesswire